+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Fosamax"

From
Osteoporosis Market and Forecast Analysis - Product Thumbnail Image

Osteoporosis Market and Forecast Analysis

  • Report
  • January 2019
  • 212 Pages
  • Global
From
Fosamax - API Insight, 2022 - Product Thumbnail Image

Fosamax - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Fosamax- Drug Insight, 2019 - Product Thumbnail Image

Fosamax- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 5 Results (Page 1 of 1)
Loading Indicator

Fosamax is a drug used to treat musculoskeletal disorders, such as osteoporosis and Paget's disease. It is a bisphosphonate, a type of drug that helps to reduce bone loss and increase bone density. Fosamax is used to prevent and treat osteoporosis in postmenopausal women, as well as to treat Paget's disease in adults. It is also used to treat osteoporosis in men and women who are taking glucocorticoids, a type of steroid medication. Fosamax is available in both oral and intravenous forms. The oral form is taken once daily, while the intravenous form is administered once every three months. Common side effects of Fosamax include nausea, diarrhea, and abdominal pain. The Fosamax market is highly competitive, with many companies offering similar products. Some of the major players in the market include Merck & Co., Inc., Novartis AG, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. Other companies in the market include Amgen Inc., Eli Lilly and Company, and GlaxoSmithKline plc. Show Less Read more